Ideaya Biosciences Stock Jumps on Promising Eye Cancer Treatment Results
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
/ 10 items
#PFE↓
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
AstraZeneca Secures Tariff Relief by Pledging Deep Drug Discounts and $50 Billion U.S. Investment
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
TrumpRx Expands: Drugmakers, Pharmacies, and GoodRx Join the Discount Site
The Trump administration is working on "TrumpRx," a new site connecting consumers to drugmakers, pharmacies, and discount programs like GoodRx to help lower prescription costs.
European Drugmakers Surge: Pfizer's US Pricing Deal Offers a Tariff Blueprint
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Pfizer Acquires Metsera for Obesity Drug Pipeline Expansion
Pfizer is buying Metsera for $4.9 billion to gain promising new obesity drugs. The portfolio includes four clinical treatments, like once-a-month shots and future oral pills, aiming for better efficacy and easier patient use to fight the growing obesity epidemic.